Agenda

Please check back shortly for the latest agenda.

Thursday, Sep 26 Friday, Sep 27

Thursday, September 26, 2024

08:30 am - 08:45 am EST
Welcome Remarks

Session I:  From Cytokines to Cells for Melanoma

 

08:45 am - 09:00 am EST
The First Effective ‘Checkpoint’ Therapy – Interleukin 2

 

Michael T. Lotze, M.D., University of Pittsburgh

09:00 am - 09:15 am EST
The Early Preclinical Studies of LAK Cells, IL-2 and Other Cytokines

 

James Mulé, IPh.D., Moffitt Cancer Center

09:15 am - 09:40 am EST
The Evolving Therapeutic Landscape of Metastatic Melanoma

 

Stephanie Goff, M.D., Center for Cancer Research, NCI

09:40 am - 09:55 am EST
BREAK

SESSION II: Antigen Discovery

 

09:55 am - 10:10 am EST
Identification of Human Tumor Antigens Recognized by Tumor Infiltrating T Cells

 

Yutaka Kawakami, M.D., Ph.D., International University of Health and Welfare

10:10 am - 10:35 am EST
Use of Personalized T Cell Antigen Screening Approaches to Develop Effective Adoptive Immunotherapies

Paul Robbins, Ph.D., Center for Cancer Research, NCI

10:35 am - 11:00 am EST
Stocking the TCR Library Targeting Shared Neoantigens

 

James Yang, M.D., Center for Cancer Research, NCI

11:00 am - 11:25 am EST
Exploring the Immunogenicity of Novel Sources or Tumor Antigens

Alena Gros, Ph.D., Vall D'Hebon Institute of Oncology

11:25 am - 11:50 am EST
Targeting the Invisible: Novel T-Cell Strategies for Overcoming MHC-Loss in Tumor

 

Ken-Ichi Hanada, Ph.D., Center for Cancer Research, NCI

11:50 am - 01:20 pm EST
LUNCH & POSTER SESSION

FAES Terrace

SESSION III: Bench to Bedside:  TIL and T-Cell Receptor Therapy
Moderator:  Stephanie Goff, M.D., Center for Cancer Research, NCI

 

01:20 pm - 01:30 pm EST
Dr. Steven Rosenberg Introduction

 

 

Monica Bertagnolli, M.D., Director, National Institutes of Health

01:30 pm - 01:55 pm EST
Neoantigen-Reactive TIL for the Treatment of Common Epithelial Cancers

 

Steven Rosenberg, M.D., Ph.D., Center for Cancer Research, NCI 

01:55 pm - 02:10 pm EST
Origins of TCR Gene Therapy for Cancer

 

 

Richard Morgan, Ph.D., Be Biopharma

02:10 pm - 02:35 pm EST
Identification of Neoantigen Reactive T Cell Receptors from Tumor Infiltrating Lymphocytes

Maria Parkhurst, Ph.D., Center for Cancer Research, NCI

02:35 pm - 03:00 pm EST
Identifying Tumor-Reactive TCRs for Therapy Based on NeoTCR Signatures

 

Frank Lowery, Ph.D., Center for Cancer Research, NCI

03:00 pm - 03:35 pm EST
Enhancing TCR-based Cell Therapies with Chimeric Cytokine Receptors

 

Eric Tran, Ph.D., Providence Cancer Institute

03:25 pm - 03:40 pm EST
BREAK

Session IV: Bench to Bedside: Chimeric Antigen Receptor Therapy
 

 

03:40 pm - 03:55 pm EST
The History of Gene Modified T-Cells: From Microinjection to CRISPR Technology

Patrick Hwu, M.D., Moffitt Cancer Center

03:55 pm - 04:20 pm EST
Genetically Modified T-Cell Therapies for Hematologic Malignancies

 

James Kochenderfer, M.D., Center for Cancer Research, NCI

04:20 pm - 04:45 pm EST
CAR T Cells for Solid Tumors: Charting a Path Forward

 

 

Crystal Mackall, M.D., Stanford University

04:45 pm EST
Adjourn for the day

Friday, September 27, 2024

08:30 am - 08:35 am EST
Welcome

SESSION V: Advances in Checkpoint Inhibitor Blockade

 

 

08:35 am - 09:00 am EST
Origins of Checkpoint Inhibitor Therapy

 

 

James Allison, Ph.D., MD Anderson Cancer Center

09:00 am - 09:25 am EST
PD-1 Pathway Blockade: State of the Art and Future Development

 

Suzanne Topalian, M.D., Johns Hopkins University

SESSION VI: Optimizing Cell Phenotype for Clinical Translation

 

 

09:25 am - 09:50 am EST
Engineering and Characterizing the Epigenetic Landscapes of T Cells with Curative Potential

Nicholas Restifo, M.D., Marble Therapeutics

09:50 am - 10:15 am EST
Understanding and Leveraging Human Neoantigen-Specific T Cell Phenotypes to Improve Cellular Immunotherapy

 

Sri Krishna, Ph.D., Center for Cancer Research, NCI

10:15 am - 10:40 am EST
Leveraging Potent T Helper Lymphocytes for Therapeutic Good Against Solid Tumors

Chrystal Paulos, Ph.D., Winship Cancer Institute at Emory University 

10:40 am - 10:55 am EST
BREAK

SESSION VII: Optimizing Tumor Microenvironment for Clinical Translation

 

 

10:55 am - 11:15 am EST
Targeting the Microbiome to Promote Health and End Cancer

 

Jennifer Wargo, M.D. MD Anderson Cancer Center

11:15 am - 11:30 am EST
Deep Investigations in the Tumor Microenvironment Pave the Way for New Cell Therapy Approaches

Rosandra Kaplan, M.D., Center for Cancer Research, NCI

11:30 am - 11:40 am EST
Presentation of 50 Year Service Award to Steven Rosenberg, M.D., Ph.D.

Award presented by Kimryn Rathmell, M.D., Ph.D., Director, National Cancer Institute

11:40 am - 11:45 am EST
Closing Remarks